Bio-Rad Laboratories, Inc.
In the published model solve dated 2026-Q2, anchored at $329.94, Bio-Rad Laboratories, Inc. (BIO) is priced for +9.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Management cut the full-year outlook in April, guiding 2026 currency-neutral revenue to a range running from minus 3% to plus 0.5%, with Life Science at minus 3% to minus 1% [Source: Bio-Rad Q1 2026 results, April 2026]. • Roughly three fifths of the company's market value is an equity stake in another business rather than the laboratory operation itself, and a $562 million swing in the value of that stake drove the reported first-quarter loss [Source: Bio-Rad Q1 2026 results, April 2026]. • T
Is BIO overvalued? See what's priced in →
376 institutional managers reported holding BIO in 13F filings for the quarter ended 2026-03-31. Together they hold about 74% of the company; the top 10 hold 40%. 52 opened new positions that quarter. Held by First Eagle Investment Management, Vanguard Group, BlackRock, among others. On the short side, 1.5M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BIO has cut its share count 9.4% over the past five years, spending $1.19B on repurchases. It pays no dividend. Cash returned over the past three years: $768.22M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BIO over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BIO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -1.0% | -10.7% |
| 2023-10-28 | -6.6% | +19.4% |
| 2024-02-17 | +4.0% | -18.0% |
| 2024-05-09 | -4.8% | +6.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BIO's latest 8-K filings: 2026-04-30 (items 2.02, 7.01, 9.01); 2026-04-24 (items 5.02, 5.07, 9.01); 2026-02-19 (items 7.01); 2026-02-12 (items 2.02, 7.01, 9.01); 2025-10-29 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.